A rare lupus randomization, among the first worldwide | Stryde Research News
In a global lupus study, Stryde delivered one of only a handful of randomizations achieved anywhere so far.
Stryde at the Lupus & You Empowerment Conference | Stryde Research News
Our lupus team joined the Lupus Foundation of America’s conference in Dallas to connect with patients and advocates.
First patient worldwide dosed in a Phase 2 angiokeratoma trial | Stryde Research News
One of our sites became the first in the world to enroll and dose a patient in a Phase 2 angiokeratoma study.
First patient randomized in a groundbreaking skin cancer trial | Stryde Research News
Stryde randomized its first patient in a skin cancer study testing a new, less invasive injection-based treatment.